Candel Therapeutics (CADL) Shares Outstanding (Weighted Average) (2020 - 2025)

Candel Therapeutics' Shares Outstanding (Weighted Average) history runs 6 years deep, the most recent figure standing at $53.0 million for Q4 2025.

• In Q4 2025, Shares Outstanding (Weighted Average) rose 67.19% year-over-year to $53.0 million; the TTM figure through Dec 2025 stood at $53.0 million (up 67.19% YoY), while the FY2025 annual figure was $53.0 million, up 67.19% from the prior year.
• Shares Outstanding (Weighted Average) came in at $53.0 million for Q4 2025 at Candel Therapeutics, down from $54.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $54.9 million in Q3 2025 to a low of $11.6 million in Q1 2021.
• A 5-year average of $31.3 million and a median of $28.9 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• Across the five-year window, Shares Outstanding (Weighted Average) surged 146.32% in 2022 and grew 0.39% in 2023, its largest moves.
• Candel Therapeutics' Shares Outstanding (Weighted Average) stood at $18.9 million in 2021, then jumped by 52.72% to $28.8 million in 2022, then advanced by 0.39% to $28.9 million in 2023, then increased by 9.47% to $31.7 million in 2024, then surged by 67.19% to $53.0 million in 2025.
• According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $53.0 million, $54.9 million, and $51.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison